Chemical inhibitors of Cyp2c37 include a variety of compounds that can interact with the enzyme to reduce its activity through different mechanisms. Sulfaphenazole, for instance, is a selective CYP2C inhibitor that competes with the natural substrates of Cyp2c37, binding to its active catalytic site and thereby reducing the enzyme's metabolic function. Similarly, the flavonoid quercetin also binds to the active site of Cyp2c37, preventing the enzyme from interacting with its intended substrates. Clopidogrel, through its metabolism, can form a reactive metabolite that irreversibly binds to Cyp2c37, resulting in a sustained decrease in enzyme activity. Montelukast operates on the same principle by competing for the substrate binding sites on Cyp2c37, thus impeding the enzyme's ability to metabolize other compounds effectively.
Further, inhibitors such as fluconazole and ketoconazole target the heme group within Cyp2c37. Fluconazole binds to this group, which is vital for the enzyme's catalytic action, thus inhibiting its function. Ketoconazole similarly interferes with the heme iron center of Cyp2c37, blocking the enzymatic processing of its substrates. Triclabendazole and methoxsalen employ a slightly different approach; triclabendazole inhibits by binding to the active site of Cyp2c37, reducing its activity, while methoxsalen acts as a mechanism-based inhibitor forming a covalent bond with the active site, leading to irreversible inhibition. Phenylbutazone and diclofenac both inhibit Cyp2c37 through competitive inhibition by occupying the active site and preventing substrate metabolism. Diclofenac achieves this through a metabolite that binds irreversibly to the enzyme. Chloramphenicol inhibits by directly binding to the active site of Cyp2c37, while proadifen, or SKF-525A, reduces the enzyme's catalytic efficiency by non-selectively binding to multiple sites on Cyp2c37. These chemical interactions all serve to inhibit the normal function of Cyp2c37 by preventing its usual metabolic processing of substrates.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin is a flavonoid that can inhibit various CYP enzymes. It inhibits Cyp2c37 by binding to the enzyme's active site, preventing its normal interaction with substrates. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $120.00 | 1 | |
Clopidogrel is metabolized by CYP enzymes and can inhibit Cyp2c37 by forming a reactive metabolite that irreversibly binds to the enzyme, leading to a decrease in its activity. | ||||||
Montelukast Sodium | 151767-02-1 | sc-202231 sc-202231A sc-202231B | 10 mg 25 mg 250 mg | $50.00 $83.00 $158.00 | 5 | |
Montelukast is metabolized by CYP2C enzymes and can inhibit Cyp2c37 by competing with its substrates for binding sites, thus reducing the enzyme's capacity to metabolize other compounds. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $53.00 $84.00 | 14 | |
Fluconazole is known to inhibit several CYP enzymes, and it can inhibit Cyp2c37 by binding to the heme group of the enzyme, which is essential for its catalytic activity. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole inhibits CYP enzymes by interfering with their heme iron center. It can inhibit Cyp2c37 by binding to the enzyme's heme group, preventing the metabolic processing of substrates. | ||||||
Triclabendazole | 68786-66-3 | sc-213105 sc-213105A | 100 mg 1 g | $104.00 $120.00 | ||
Triclabendazole is metabolized by CYP enzymes and can inhibit Cyp2c37 by binding to the active site, which leads to a decrease in enzyme activity. | ||||||
Methoxsalen (8-Methoxypsoralen) | 298-81-7 | sc-200505 | 1 g | $27.00 | 1 | |
Methoxsalen is a mechanism-based inhibitor of some CYP enzymes. It can inhibit Cyp2c37 by forming a covalent bond with the active site, leading to irreversible inhibition. | ||||||
Phenylbutazone | 50-33-9 | sc-204843 | 5 g | $31.00 | 1 | |
Phenylbutazone can inhibit Cyp2c37 by competing with its natural substrates at the active site, thus reducing the enzyme's activity. | ||||||
Diclofenac Sodium | 15307-79-6 | sc-202136 sc-202136A | 5 g 25 g | $40.00 $125.00 | 4 | |
Diclofenac is metabolized by CYP2C enzymes and can inhibit Cyp2c37 by mechanism-based inhibition, where the metabolite formed during the process binds irreversibly to the enzyme. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $53.00 | 10 | |
Chloramphenicol is an inhibitor of CYP enzymes and can inhibit Cyp2c37 by binding to the active site, thereby inhibiting the enzyme's activity. | ||||||